OEM Supply Covid-19 Neutralizing Antibody - Troponin I (cTnI) – Joinstar

Short Description:

Product Detail

Product Tags

Related Video

Feedback (2)

To consistently enhance the management method by virtue of the rule of "sincerely, fantastic religion and top quality are the base of business development", we extensively absorb the essence of associated goods internationally, and constantly acquire new merchandise to satisfy the needs of shoppers for Covid Test, Covid-19 Rt-Pcr, Igg/Igm Rapid Test Supplier, If you are looking for a good quality, fast delivery, best after service and good price supplier in China for long-term business relationship, we will be your best choice.
OEM Supply Covid-19 Neutralizing Antibody - Troponin I (cTnI) – Joinstar Detail:

Kit Name: Joinstar Troponin I Detection Kit

Method: Fluorescence dry quantitative immunoassay

Assay measuring range: 0.05ng/mL~30.00ng/mL

Incubation time: 15min

Sample: Human serum, plasma (EDTA anticoagulant), whole blood (EDTA anticoagulant)

Reference range: ≤0.40 ng/mL

Storage and Stability: 

The Detection Kit is stable for 12 months at 2°~30°C.

Troponins are arranged in a heterotrimeric complex consisting of 3 troponin molecules, whose names are derived from their functions: calcium-binding troponin C (TnC; 18 kDa), inhibitory troponin I (TnI; 24 kDa), and tropomyosin-binding troponin T (TnT; 37 kDa).
Troponins are protein components of striated muscle. There are three different troponins: troponin C, troponin T and troponin I. Troponins I (cTnI) and T (cTnT) are only found in cardiac muscle.
Under normal conditions, cTnI is not detected in the blood of healthy people and minor myocardial damage can cause a significant increase in serum cTnI levels.
The level of cTnI in serum increases at 4-8h after myocardial injury, peak at 18-24h, lasts for a long time (5-8 days), and basically returns to normal around 10 days.

《2021 AHA/ACC/ASE/CHEST/SAEM/SCCT/SCMR Guideline for the Evaluation and Diagnosis of Chest Pain: A Report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines》
In the evaluation of patients presenting with acute chest pain and suspected acute coronary syndrome (ACS) for whom serial troponins are indicated to exclude myocardial injury, recommended time intervals after the initial troponin sample collection (time zero) for repeat measurements are: 1 to 3 hours for high-sensitivity troponin and 3 to 6 hours for conventional troponin assays.
《Fourth Universal Definition of Myocardial Infarction (2018) 》
The term myocardial injury should be used when there is evidence of elevated cardiac troponin values (cTn) with at least one value above the 99th percentile upper reference limit (URL). The myocardial injury is considered acute if there is a rise and/or fall of cTn values.
《Clinical Laboratory Practice Recommendations for the Use of Cardiac Troponin in Acute Coronary Syndrome: Expert Opinion from the Academy of the American Association for Clinical Chemistry and the Task Force on Clinical Applications of Cardiac Bio-Markers of the International Federation of Clinical Chemistry and Laboratory Medicine(2018)》
Cardiac troponin results should be reported within 60 minutes or less of when a sample is received. There should be continued efforts to improve this to a time of 60 minutes from when the sample was collected.
cTnI and cTnT are the biomarkers of choice for the diagnosis of acute myocardial infarction (AMI) and risk-outcomes stratification.
《2017 ACC/AHA/HFSA Focused Update of the 2013 ACCF/AHA Guideline for the Management of Heart Failure》
Troponins I and T respond similarly for acute coronary syndromes and acute decompensated HF. Elevations in either troponin I or T levels in the setting of acute HF are of prognostic significance and must be interpreted in the clinical context.
Measurement of baseline levels of natriuretic peptide biomarkers and/or cardiac troponin on admission to the hospital is useful to establish a prognosis in acutely decompensated heart failure.

The “Gold Standard” for the diagnosis of AMI
Diagnosis of early myocardial injury
Diagnosis, risk stratification, prognosis assessment of ACS
Differential diagnosis of various causes of chest pain
Assessment of infarct area and degree of cardiac function impairment

Product detail pictures:

OEM Supply Covid-19 Neutralizing Antibody - Troponin I (cTnI) –  Joinstar detail pictures

Related Product Guide:

abide by the contract", conforms on the market requirement, joins within the market competition by its superior quality likewise as provides far more comprehensive and great company for shoppers to let them develop into huge winner. The pursue on the corporation, is definitely the clients' gratification for OEM Supply Covid-19 Neutralizing Antibody - Troponin I (cTnI) – Joinstar , The product will supply to all over the world, such as: Sacramento, Tanzania, Greece, We have more than 10 years exported experience and our products have expored more than 30 countries around the word . We always hold the service tenet Client first,Quality first in our mind,and are strict with product quality. Welcome your visiting!
  • Superb technology, perfect after-sales service and efficient work efficiency, we think this is our best choice.
    5 Stars By Mike from Kazakhstan - 2017.10.27 12:12
    Sales manager is very enthusiastic and professional, gave us a great concessions and product quality is very good,thank you very much!
    5 Stars By Mary from Nepal - 2017.02.18 15:54
    Write your message here and send it to us